Maintaining momentum on the path to the post-pandemic world

Medical products regulators around the world are at an inflection point. Decisions they make now — or don’t make — will determine whether COVID-induced innovations persist or fade away. The stakes are high: successful integration of the most pertinent pandemic policies could be a springboard for faster, more efficient development of medicines.

There is also a danger, the Charles Forum warns in a new white paper, that regulators around the world will respond to the challenge inconsistently, creating inefficiencies that would slow the development and deployment of medicines and put supply chains at risk. ...